| HOME >> BIOLOGY >> TECHNOLOGY |
PASADENA, Calif., Nov. 7 /PRNewswire-FirstCall/ -- AutoImmune Inc. (OTC Bulletin Board: AIMM) today reported a net loss of $23,000, or break even per share basic and diluted, for the three months ended September 30, 2008, compared with a net loss of $8,000, or break even per share basic and diluted, for the three months ended September 30, 2007. For the nine months ended September 30, 2008, the net loss was $216,000, or $0.01 per share basic and diluted, compared with net loss of $62,000, or break even per share basic and diluted for the same period in 2007. As of September 30, 2008, the Company reported $8.6 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.
Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, "Product sales at Colloral LLC during the third quarter were unchanged from the same period prior year." AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46 "Consolidation of Variable Interest Entities."
AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, MBP8298, if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. During the third quarter just completed, BioMS announced the product was granted fast track designation by the FDA and that it had received a milestone payment from Eli Lilly for successfully passing an interim analysis for safety and futility in its pivotal phase II/III trial of MBP8208 for treatment of secondary progressive multiple sclerosis. We expect the final trial data will be available during the second half of 2009.
AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.
Statements in this release that are not strictly historical are
forward-looking statements including statements about clinical trials and
studies and future sales, royalties and revenue. You can identify these
forward-looking statements because they involve our expectations, beliefs,
projections, anticipations or other characterizations of future events or
circumstances. These forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that may
cause actual results to differ materially from those in the forward-looking
statements as a result of any number of factors. These factors include, but
are not limited to the uncertainties of clinical trial results, the
Company's dependence on third parties for licensing revenue, and the risks
of technological change and competition. These factors are more fully
discussed, as are other factors, in the Company's most recent Annual Report
on Form 10-KSB filed with the Securities and Exchange Commission in the
section entitled "Risk Factors."
- Financial Chart Follows -
AUTOIMMUNE INC.
STATEMENT OF OPERATIONS
(Unaudited)
Three months ended Nine months ended
September 30, September 30,
2007 2008 2007 2008
Revenue $59,000 $57,000 $219,000 $225,000
Costs and expenses:
Cost of revenue 9,000 1,000 20,000 29,000
Research and
development 7,000 3,000 95,000 93,000
Selling, general
and administrative 163,000 125,000 532,000 511,000
Total costs and
expenses 179,000 129,000 647,000 633,000
Interest income 112,000 51,000 335,000 195,000
Minority interest
in joint venture - (2,000) 6,000 (3,000)
Other income - - 25,000 0
112,000 49,000 366,000 192,000
Net loss ($8,000) ($23,000) ($62,000) ($216,000)
Net loss per share -
basic ($0.00) ($0.00) ($0.00) ($0.01)
Net loss per share -
diluted ($0.00) ($0.00) ($0.00) ($0.01)
Weighted average
common shares
outstanding - basic 16,979,623 16,999,623 16,967,504 16,998,820
Weighted average
common shares
outstanding -
diluted 16,979,623 16,999,623 16,967,504 16,998,820
CONDENSED BALANCE SHEET
(Unaudited)
December 31, September 30,
2007 2008
Cash and marketable securities $8,804,000 $8,591,000
Other current assets 167,000 154,000
Total assets $8,971,000 $8,745,000
Current liabilities $128,000 $129,000
Minority interest in joint venture 11,000 24,000
Total stockholders' equity 8,832,000 8,592,000
Total liabilities and equity $8,971,000 $8,745,000
'/>"/>
| SOURCE AutoImmune Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. AutoImmune Inc. Reports 2008 Second Quarter Financial Results
2. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
3. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes - Correction
4. QED International Associates Announces Changes to the HealthShares(TM) Autoimmune-Inflammation and Neuroscience Indexes
5. Dendreon Reports Third Quarter 2008 Financial Results
6. Osteotech Reports 2008 Third Quarter Financial Results
7. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
8. Oncothyreon reports third quarter 2008 financial results
9. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
10. NeurogesX Reports Third Quarter 2008 Results
11. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |